Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2012 Filed Feb 22, 2012 22:53 UTC |
Fussell Stephen RSenior Vice President
|
GrantOption (right to buy) · Derivative | 44,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003234 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common shares · 44,000 shares Expires 2022-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,667 on 02/17/2013, 14,666 on 02/17/2014, and 14,667 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:53 UTC |
Fussell Stephen RSenior Vice President
|
GrantCommon shares without par value | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003234 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,566 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:55 UTC |
ALBAN CARLOSSenior Vice President
|
GrantOption (right to buy) · Derivative | 48,100 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003235 · edgar.xml · derivative · entry 4 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,100 Underlying: Common shares · 48,100 shares Expires 2022-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,034 on 02/17/2013, 16,033 on 02/17/2014, and 16,033 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:55 UTC |
ALBAN CARLOSSenior Vice President
|
GrantCommon shares without par value | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003235 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,974 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:00 UTC |
Warmuth Michael JSenior Vice President
|
GrantOption (right to buy) · Derivative | 48,100 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003237 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,100 Underlying: Common shares · 48,100 shares Expires 2022-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,034 on 02/17/2013, 16,033 on 02/17/2014, and 16,033 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:56 UTC |
Schumacher Laura JExecutive Vice President
|
GrantOption (right to buy) · Derivative | 79,800 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003236 · edgar.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,800 Underlying: Common shares · 79,800 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,600 on 02/17/2013, 26,600 on 02/17/2014, and 26,600 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:56 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon shares without par value | 44,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003236 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,130 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:01 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 34,400 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003239 · edgar.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Underlying: Common shares · 34,400 shares Expires 2022-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,467 on 02/17/2013, 11,466 on 02/17/2014, and 11,467 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:01 UTC |
LINDER GREG WVice President
|
GrantCommon shares without par value | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003239 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,577 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:02 UTC |
Hance Robert BSenior Vice President
|
GrantOption(right to buy) · Derivative | 44,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003242 · edgar.xml · derivative · entry 6 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common shares · 44,000 shares Expires 2022-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,667 on 02/17/2013, 14,666 on 02/17/2014, and 14,667 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:02 UTC |
Hance Robert BSenior Vice President
|
GrantCommon shares without par value | 24,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003242 · edgar.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,696 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:03 UTC |
Mason Heather LSenior Vice President
|
GrantOption (right to buy) · Derivative | 41,200 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003245 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common shares · 41,200 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,734 on 02/17/2013, 13,733 on 02/17/2014, and 13,733 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:03 UTC |
Mason Heather LSenior Vice President
|
GrantCommon shares without par value | 22,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003245 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,173 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:07 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantOption (right to buy) · Derivative | 302,500 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003249 · edgar.xml · derivative · entry 5 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,500 Underlying: Common shares · 302,500 shares Expires 2022-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 100,834 on 02/17/2013, 100,833 on 02/17/2014, and 100,833 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:07 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GrantCommon shares without par value | 167,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003249 · edgar.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,328,116 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:08 UTC |
GONZALEZ RICHARD AExecutive Vice President
|
GrantOption (right to buy) · Derivative | 107,300 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003250 · edgar.xml · derivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,300 Underlying: Common shares · 107,300 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,767 on 02/17/2013, 35,766 on 02/17/2014, and 35,767 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:08 UTC |
GONZALEZ RICHARD AExecutive Vice President
|
GrantCommon shares without par value | 59,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003250 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,162 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:09 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 52,300 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003251 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,300 Underlying: Common shares · 52,300 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,434 on 02/17/2013, 17,433 on 02/17/2014, and 17,433 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:09 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 28,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003251 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,435 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:13 UTC |
ASHLEY RICHARD WExecutive Vice President
|
GrantCommon shares without par value | 42,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003257 · edgar.xml · nonDerivative · entry 1 ASHLEY RICHARD W · CIK 0001278570 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,066 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:15 UTC |
MAZZO JAMES VSenior Vice President
|
GrantOption (right to buy) · Derivative | 22,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003259 · edgar.xml · derivative · entry 2 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common shares · 22,000 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,334 on 02/17/2013, 7,333 on 02/17/2014, and 7,333 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:15 UTC |
MAZZO JAMES VSenior Vice President
|
GrantCommon shares without par value | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003259 · edgar.xml · nonDerivative · entry 1 MAZZO JAMES V · CIK 0001227297 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,852 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:14 UTC |
Landgraf John CExecutive Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003258 · edgar.xml · derivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common shares · 55,000 shares Expires 2022-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 02/17/2013, 18,333 on 02/17/2014, and 18,333 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:14 UTC |
Landgraf John CExecutive Vice President
|
GrantCommon shares without par value | 30,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003258 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,611 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:16 UTC |
Blaser Brian J.Senior Vice President
|
GrantOption (right to buy) · Derivative | 48,100 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003260 · edgar.xml · derivative · entry 2 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,100 Underlying: Common shares · 48,100 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,034 on 02/17/2013, 16,033 on 02/17/2014, and 16,033 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:16 UTC |
Blaser Brian J.Senior Vice President
|
GrantCommon shares without par value | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003260 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,708 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:18 UTC |
Michael Edward L.Executive Vice President
|
GrantOption (right to buy) · Derivative | 71,500 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003261 · edgar.xml · derivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common shares · 71,500 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,834 on 02/17/2013, 23,833 on 02/17/2014, and 23,833 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:18 UTC |
Michael Edward L.Executive Vice President
|
GrantCommon shares without par value | 39,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003261 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,098 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 2,371 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · derivative · entry 7 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,371 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
SaleCommon shares without par value | 1,790 | $55.03 | $98,503.70 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · nonDerivative · entry 5 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,383 Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
SaleCommon shares without par value | 100 | $55.03 | $5,503.01 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · nonDerivative · entry 4 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,173 Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
SaleCommon shares without par value | 381 | $55.03 | $20,966.81 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · nonDerivative · entry 3 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,273 Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
SaleCommon shares without par value | 100 | $55.03 | $5,503.09 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · nonDerivative · entry 2 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,654 Read SEC document |
| February 14, 2012 Filed Feb 16, 2012 22:14 UTC |
Murray Corlis DSenior Vice President
|
Exercise / conversionCommon shares without par value | 2,371 | $53.63 | $127,144.88 |
DisclosureSEC source: 0001179110-12-002824 · edgar.xml · nonDerivative · entry 1 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 1,890 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · derivative · entry 11 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,890 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
Tax withholdingCommon shares without par value | 1,842 | $55.00 | $101,310.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,498 Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionCommon shares without par value | 1,890 | $53.63 | $101,351.25 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 51,311 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · derivative · entry 10 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 51,311 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 2,200 | $55.02 | $121,044.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,450 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 1,500 | $55.02 | $82,522.50 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,650 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 100 | $55.01 | $5,501.25 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,150 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 4,800 | $55.01 | $264,048.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,250 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 200 | $55.01 | $11,001.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,050 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
SaleCommon shares without par value | 42,511 | $55.00 | $2,338,105.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,250 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC |
Michael Edward L.Executive Vice President
|
Exercise / conversionCommon shares without par value | 51,311 | $53.63 | $2,751,552.38 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:16 UTC |
Murray Corlis DSenior Vice President
|
GrantCommon shares without par value | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-001821 · edgar.xml · nonDerivative · entry 1 Murray Corlis D · CIK 0001540988 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,383 F1 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC |
Fussell Stephen RSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 21,281 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,281 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC |
Fussell Stephen RSenior Vice President
|
SaleCommon shares without par value | 800 | $54.24 | $43,392.56 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,166 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC |
Fussell Stephen RSenior Vice President
|
SaleCommon shares without par value | 800 | $54.24 | $43,392.16 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,966 Read SEC document |
| February 01, 2012 Filed Feb 3, 2012 23:17 UTC |
Fussell Stephen RSenior Vice President
|
SaleCommon shares without par value | 300 | $54.24 | $16,272.03 |
DisclosureSEC source: 0001179110-12-001822 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,766 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.